Rosenthal Daniel H
Known title: Ch.Rev.Ofc, COO, CFOCIK: 0001827674
Rosenthal Daniel H's purchase track record
Rosenthal Daniel H has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/14/2022 | ROOT | $152K | -18.1% | -54.3% | -1.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ROOT | ▼ Sell | Tax Withholding | 385 | $2K | 2/1/2023 | View on chart |
| ROOT | ▼ Sell | Tax Withholding | 481 | $4K | 11/1/2022 | View on chart |
| ROOT | ▼ Sell | Tax Withholding | 8,647 | $9K | 8/1/2022 | View on chart |
| ROOT | ▼ Sell | Tax Withholding | 8,647 | $17K | 5/2/2022 | View on chart |
| ROOT | ▲ Buy | Grant | 676,513 | $0 | 5/2/2022 | View on chart |
| ROOT | ▲ Buy | Open Market | 100,000 | $152K | 3/14/2022 | View on chart |
| ROOT | ▲ Buy | Grant | 702,518 | $0 | 2/23/2022 | View on chart |
| ROOT | ▼ Sell | Tax Withholding | 26,433 | $56K | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Wells Fargo cuts Root price target to $47
Wells Fargo lowered its price target for Root to $47 while maintaining an Equal-Weight rating. This adjustment occurs as the stock trades near its 52-week low, with the new target sitting below the current average analyst estimate of $57. The move reflects a more cautious outlook for the insurer amidst broader industry developments.
Wells Fargo cuts Root price target to $47. Wells Fargo lowered its price target for Root to $47 while maintaining an Equal-Weight rating. This adjustment occurs as the stock trades near its 52-week low, with the new target sitting below the current average analyst estimate of $57. The move reflects a more cautious outlook for the insurer amidst broader industry developments.